Genervon Presents Mechanisms of Actions in Alzheimer’s Disease, Including Results Confirming that GM6 Attenuates Alzheimer’s Disease in Mouse Model, in Part by Reducing Inflammation

PASADENA, Calif.--(BUSINESS WIRE)--Following the closure of several research programs for Alzheimer’s disease, in early 2018 the FDA issued a release entitled “Draft Guidance for Industry: Early Alzheimer’s Disease: Developing Drugs for Treatment.” Encouraged by the proposed changes in the new guidance, Genervon’s research team reported new findings that its drug candidate GM6 attenuates Alzheimer’s disease (AD) in an early AD transgenic APP mice model. 

You are invited to our luncheon presentation - World Preclinical Congress, Translational Strategies In CNS

Mr. Winston Ko, Chairman and CEO, will present Genervon's disruptive and novel therapeutic strategy for diseases of the central nervous system and share pre-clinical and bioinformatic data as well as functional and bio-marker findings from clinical trials. Genervon has identified 1,259 genes altered greater than 2-fold in SH-5YSY cells by GM6 including 89, 48, 46 and 9 specific genes associated with ALS, AD, PD and MS respectively. GM6 discovered by Genervon is an endogenous multiple targets embryonic stage tyrosine kinase motoneuronotrophic factor neuronal regulator of the human nervous system.

Confidential data from Genervon ALS Phase 2A clinical trial were released and published

Genervon discovered the endogenous embryonic stage multi-target regulator GM6. GM6 modulates 89 ALS, 48 AD, 46 PD and 9 MS associated defective genes to bring homeostasis for the respective patient groups. Genervon embraced a system biology approach in finding a cure for the highly complex heterogeneous neurodegenerative and neurological diseases and disorders...